Table 1.
Primary disproportionality analysis of treatments.
| Outcomes | Anti-PD-1 |
Anti-PD-L1 |
Anti-CTLA-4 |
Anti-PD-1+Anti-CTLA-4 |
||||
|---|---|---|---|---|---|---|---|---|
| N | ROR (95% CI) | N | ROR (95% CI) | N | ROR (95% CI) | N | ROR (95% CI) | |
| Pneumonitis | 2994 | 1.60 (1.53, 1.68) | 1347 | 3.7 (3.47, 3.95) | 68 | 1.69 (1.31, 2.18) | 276 | 1.65 (1.45, 1.88) |
| Colitis | 1202 | 2.81 (2.58, 3.06) | 216 | 1.51 (1.31, 1.74) | 63 | 6.22 (4.77, 8.12) | 157 | 3.30 (2.79, 3.90) |
| Hepatitis | 795 | 1.45 (1.32, 1.58) | 248 | 1.94 (1.70, 2.23) | 12 | 1.08 (0.61, 1.91) | 105 | 2.24 (1.83, 2.74) |
| Myocarditis | 315 | 7.44 (5.95, 9.30) | 64 | 2.35 (1.80, 3.08) | 0 | - | 28 | 3.04 (2.06, 4.46) |
| Nephritis | 373 | 2.48 (2.15, 2.87) | 91 | 2.05 (1.64, 2.56) | 1 | 0.27 (0.04, 1.93) | 21 | 1.23 (0.80, 1.91) |
| Myositis | 728 | 2.33 (2.10, 2.58) | 110 | 1.18 (0.97, 1.44) | 5 | 0.66 (0.27, 1.59) | 25 | 0.71 (0.48, 1.06) |
| Hyperthyroidism | 325 | 8.80 (6.96, 11.13) | 50 | 1.84 (1.37, 2.48) | 2 | 1.01 (0.25, 4.08) | 32 | 3.54 (2.46, 5.09) |
| Hypothyroidism | 722 | 10.56 (8.92, 12.50) | 95 | 1.58 (1.27, 1.96) | 3 | 0.70 (0.22, 2.17) | 29 | 1.42 (0.98, 2.05) |
| Thyroiditis | 177 | 6.53 (4.91, 8.68) | 29 | 1.78 (1.21, 2.63) | 5 | 4.47 (1.84, 10.88) | 25 | 4.86 (3.21, 7.37) |
| Hypophysitis | 114 | 4.26 (3.14, 5.79) | 21 | 1.79 (1.13, 2.83) | 12 | 15.28 (8.46, 27.62) | 39 | 11.92 (8.34, 17.05) |
| Diabetes | 774 | 2.57 (2.32, 2.85) | 117 | 1.20 (1.00, 1.46) | 12 | 1.49 (0.84, 2.65) | 95 | 2.90 (2.35, 3.59) |
PD-1: programmed death–1 receptor inhibitor; PD-L1: programmed death ligand–1 inhibitor; CTLA-4: cytotoxic T lymphocyte associated antigen inhibitor; N: number; ROR: reporting odds ratio; CI: confidence interval.